Eli Lilly presented early clinical results for brenipatide, a once-weekly GIP/GLP-1 receptor agonist candidate, covering substance use, psychiatric, and immunologic indications. At Psych Congress 2026, Lilly shared dose-selection supporting data from its Phase I J2S-MC-GZMD trial (NCT06606106), including pharmacokinetic durability that extends beyond the weekly dosing interval. Lilly reported mean half-life estimates ranging from 9.08 to 12.5 days, with longer exposure tied to the highest tested dose level of 4.5 mg. The company also detailed Phase III trial design plans for major depressive disorder and alcohol use disorder, signaling a pivot from metabolic success toward neuropsychiatric and immune-driven hypotheses.